Greg Panico News
-
Eli Lilly & Co. sought to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s.
-
A Johnson & Johnson unit violated consumer-protection laws by sending South Carolina doctors a misleading letter about the safety and effectiveness of the antipsychotic drug Risperdal, a jury concluded.
-
Mark Kurland, a co-founder of New Castle Funds LLC, was ordered to serve 27 months in prison after pleading guilty in the Galleon Group LLC insider-trading case, becoming the first defendant in the scheme to be sentenced.
-
At a time when more than one in five U.S. insider-trading cases involve health-care stocks, the industry’s companies say their policies designed to prevent abuse are sufficient -- or they refuse to publicly discuss the issue at all.
-
Goldman Sachs Group Inc. Chairman Lloyd Blankfein will be called by U.S. prosecutors to testify as a government witness at the insider-trading trial of Galleon Group LLC co-founder Raj Rajaratnam.
-
BP Plc , whose potential liability for the Gulf of Mexico oil spill has lawmakers and analysts raising the specter of bankruptcy, would be unlikely to avoid paying claims by seeking court protection, Bloomberg News’ Margaret Cronin Fisk and Linda Sandler reported after speaking with restructuring experts.
-
Donald says he thought he’d died minutes after ketamine, a popular club drug known as Special K, was infused into his vein at a Sydney hospital in March.
-
Johnson & Johnson won dismissal of Pennsylvania’s suit alleging that the drugmaker hid health risks of its Risperdal antipsychotic drug and duped officials into paying millions more than they should have for the medicine.
-
Attorney Olivier Metzner says thousands of Societe Generale SA’s own computer records will clear his client, Jerome Kerviel, of responsibility for the bank’s record 4.9 billion-euro ($6 billion) trading loss, Bloomberg News’ Alan Katz and Heather Smith report.
-
Johnson & Johnson must face a trial over Arkansas officials’ claims the drugmaker hid the risks of its anti-psychotic drug Risperdal when selling it to residents covered by the state’s Medicaid program, a judge ruled.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page